Mi­graine mar­ket­ing wars? Ab­b­Vie, Bio­haven, Eli Lil­ly, Am­gen lead push for at­ten­tion in new­ly com­pet­i­tive space

For a long time, mi­graine suf­fer­ers were stuck with the same old med­i­cines and ad­vice. Try some trip­tans, change your di­et, maybe even see if a nar­cot­ic might help — but no ma­jor drug ad­vances to pre­vent or stop de­bil­i­tat­ing mi­graine episodes in al­most 30 years.

Fast for­ward to 2021. With sev­en new drug ap­provals in the past three years, the once-mori­bund mi­graine mar­ket is sud­den­ly com­pet­i­tive. That’s good news for pa­tients be­cause the new meds from Ab­b­Vie, Bio­haven, Eli Lil­ly, Am­gen, Te­va and Lund­beck of­fer a va­ri­ety of de­liv­ery meth­ods and few­er side ef­fects.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.